publication . Article . Other literature type . 2016

evaluation of two commercially available cannabidiol formulations for use in electronic cigarettes

Michelle R Peace; Karen E Butler; Carl E. Wolf; Carl E. Wolf; Justin L Poklis; Alphonse Poklis; Alphonse Poklis; Alphonse Poklis;
Open Access
  • Published: 29 Aug 2016 Journal: Frontiers in Pharmacology, volume 7 (eissn: 1663-9812, Copyright policy)
  • Publisher: Frontiers Media SA
Abstract
With 24 states and the District of Columbia with laws legalizing marijuana in some form, suppliers of legal marijuana have developed Cannabis sativa products for use in electronic cigarettes. Personal battery powered vaporizers or electronic cigarettes were developed to deliver a nicotine vapor such that smokers could simulate smoking tobacco without the inherent pathology of inhaled tobacco smoke. The liquid formulations used in these devices are comprised of an active ingredient such as nicotine mixed with glycerin and/or propylene glycol and flavorings. A significant active ingredient of Cannabis sativa, cannabidiol, has been purported to have anti-convulsant...
Subjects
free text keywords: Smoking Tobacco, Pharmacology, Active ingredient, Drug, media_common.quotation_subject, media_common, Cannabidiol, medicine.drug, medicine, business.industry, business, Propylene glycol, chemistry.chemical_compound, chemistry, Tobacco smoke, Nicotine, Flavoring Agents, electronic cigarettes, vaping, e-liquids, DART-MS, HPLC-MS/MS, Perspective, cbd, Therapeutics. Pharmacology, RM1-950
Funded by
NIH| Central Va Ctr on DA Research
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 5P30DA033934-03
  • Funding stream: NATIONAL INSTITUTE ON DRUG ABUSE
34 references, page 1 of 3

Bao M.Joza P.Ricket W. S.Lauterback J. H. (2010). An improved headspace solid-phase microextraction method for the analysis of free-base nicotine in particulate phase of mainstream cigarette smoke. Anal. Chim. Acta 663 49–54. 10.1016/j.aca.2010.01.036 20172096 [OpenAIRE] [PubMed] [DOI]

Bekki K.Uchiyama S.Ohta K.Inaba Y.Nakagome H.Kunugita N. (2014). Carbonyl compounds generated from electronic cigarettes. Int. J. Environ. Res. Public Health 11 11192–11200. 10.3390/ijerph111111192 25353061 [OpenAIRE] [PubMed] [DOI]

Bhattacharyya S.Morrison P. D.Fusar-Poli P.Martin-Santos R.Borgwardt S.Winton-Brown T. (2010). Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 35 764–774. 10.1038/npp.2009.184 19924114 [OpenAIRE] [PubMed] [DOI]

Breland A.Soule E.Lopez A.Ramôa C.El-Hellani A.Eissenberg T. (2016). Electronic cigarettes: what are they, and what do they do? Ann. N. Y. Acad Sci. 10.1111/nyas.12977 [Epub ahead of print]. [OpenAIRE] [DOI]

Brenneisen R. (2007). “Chemistry and analysis of phytocannabinoids and other cannabis constituents,” in Marijuana and the Cannabinoids ed. Elsohly M. (Totowa, NJ: Human Press) 17–51. [OpenAIRE]

Cloud 9 Hemp (2015). Cloud 9 Hemp,” Cloud9hemp. com, Last Modified. Available at: https://cloud9hemp.com/ (accessed May 10 2016).

Etter J. F.Zather E.Svensson S. (2013). Analysis of refill liquids for electronic cigarettes. Addiction 108 1671–1679. 10.1111/add.12235 23701634 [OpenAIRE] [PubMed] [DOI]

Fischer B.Kuganesan S.Gallassi A.Malcher-Lopes R.van den Brink W.Wood E. (2015). Addressing the stimulant treatment gap: a call to investigate the therapeutic benefits potential of cannabinoids for crack-cocaine use. Int. J. Drug Policy 26 1177–1182. 10.1016/j.drugpo.2015.09.005 26500166 [OpenAIRE] [PubMed] [DOI]

Flora J. W.Meruva N.Huang C. B.Wilkinson C. T.Ballentine R.Smith D. C. (2016). Characterization of potential impurities and degradation products in electronic cigarette formulations and aerosols. Regul. Toxicol. Pharmacol. 74 1–11. 10.1016/j.yrtph.2015.11.009 26617410 [OpenAIRE] [PubMed] [DOI]

Friedman D.Devinsky O. (2015). Cannabinoids in the treatment of epilepsy. N. Engl. J. Med. 373 1048–1058. 10.1056/NEJMra1407304 26352816 [OpenAIRE] [PubMed] [DOI]

Goniewicz M. L.Hajek P.McRobbie H. (2014). Nicotine content of electronic cigarettes, its release in vapour and its consistency across batches: regulatory implications. Addiction 109 500–507. 10.1111/add.12410 24345184 [OpenAIRE] [PubMed] [DOI]

Goniewicz M. L.Kuma T.Gawron M.Knysak J.Kosmider L. (2013). Nicotine levels in electronic cigarettes. Nicotine Tob. Res. 15 158–166. 10.1093/ntr/nts103 22529223 [OpenAIRE] [PubMed] [DOI]

Isodiol. (2016). “Disclaimer,” Isodiol.com, Last Modified. Available at: http://www.isodiol.com/#!disclaimer/oztke

Jensen R. P.Luo W.Pankow J. F.Strongin R. M.Peyton D. H. (2015). Hidden formaldehyde in e-cigarette aerosols. N. Engl. J. Med. 372 392–394. 10.1056/NEJMc1413069 25607446 [PubMed] [DOI]

Johnson J. R.Burnell-Nugent M.Lossignol D.Ganae-Motan E. D.Potts R.Fallon M. T. (2010). Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J. Pain Symptom Manage. 39 167–179. 10.1016/j.jpainsymman.2009.06.008 19896326 [OpenAIRE] [PubMed] [DOI]

34 references, page 1 of 3
Powered by OpenAIRE Open Research Graph
Any information missing or wrong?Report an Issue
publication . Article . Other literature type . 2016

evaluation of two commercially available cannabidiol formulations for use in electronic cigarettes

Michelle R Peace; Karen E Butler; Carl E. Wolf; Carl E. Wolf; Justin L Poklis; Alphonse Poklis; Alphonse Poklis; Alphonse Poklis;